Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor–host interface

@article{Hori2014PreventionOC,
  title={Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor–host interface},
  author={K. Hori and H. Akita and H. Nonaka and Akira Sumiyoshi and Y. Taki},
  journal={Cancer Science},
  year={2014},
  volume={105},
  pages={1196 - 1204}
}
  • K. Hori, H. Akita, +2 authors Y. Taki
  • Published 2014
  • Biology, Medicine
  • Cancer Science
  • Combretastatins interrupt blood flow of solid tumor vascular networks and lead to necrosis by blocking nutrients. However, tumors recover from tumor blood flow interruption‐induced damage and develop viable rims. To investigate why cancer recurs and its prevention, we used a combretastatin derivative, Cderiv (=AC7700), and analyzed changes in tumor–host interface (T‐HI) vessels, which were closest to cancer cells in the tumor margin after tumor vessel disruption, and the microenvironment… CONTINUE READING
    5 Citations

    Topics from this paper.

    Combretastatins: More Than Just Vascular Targeting Agents?
    • 40
    • PDF
    Running Title : Combretastatins : more than just vascular targeting agents ?

    References

    SHOWING 1-10 OF 39 REFERENCES
    Vascular Targeting Agents as Cancer Therapeutics
    • P. Thorpe
    • Medicine
    • Clinical Cancer Research
    • 2004
    • 529
    • PDF
    Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
    • 133
    Vascular disrupting agents: a new class of drug in cancer therapy.
    • A. Gaya, G. J. Rustin
    • Medicine
    • Clinical oncology (Royal College of Radiologists (Great Britain))
    • 2005
    • 125